2022. IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation. Biomolecules and Biomedicine. 22, 4 (Jul. 2022), 580–592. DOI:https://doi.org/10.17305/bjbms.2022.7279.